Owning a patented molecule does not necessarily mean owning the innovation behind it. As AI transforms drug discovery, companies must understand how data, platforms, collaborations, and IP agreements shape long-term ownership, commercialization, and competitive advantage.

Explore Hylton-Rodic Law’s Q2 2026 highlights, including our new Adams Morgan office, AI patent strategy discussions, industry events, educational programming, and continued growth serving innovators in life sciences and technology.

AI is accelerating drug discovery and compressing the timeline for critical intellectual property decisions. This article explores how biotech and pharmaceutical companies can build stronger patent strategies, documentation practices, and decision frameworks to protect innovation and long-term enterprise value.